Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 21 to 30 of 537 total matches.
Comparison Table: Some Topical Drugs for Rosacea (online only)
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
in women
Apply once/day 481.60/30 g
637.50/30 g
Ivermectin – generic
Soolantra (Galderma)
1% cream Yes ...
View the Comparison Table: Some Topical Drugs for Rosacea
Med Lett Drugs Ther. 2024 Feb 5;66(1695):e22 doi:10.58347/tml.2024.1695c | Show Introduction Hide Introduction
Addendum: Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
Treatment of Atrial Fibrillation (Med Lett Drugs Ther 2024; 66:1)
The Interruption ...
The Interruption of Anticoagulation section of our article on Treatment of Atrial Fibrillation cited the recommendations of the American College of Chest Physicians on perioperative management of antithrombotic therapy (JD Douketis et al. Chest 2022; 162:e207). A reader suggested that our general statement on when to discontinue an oral anticoagulant would have benefited from inclusion of the recommendations of the American College of Cardiology/American Heart Association (JA Joglar et al. Circulation 2024; 149:e1). Recommendations for periprocedural management of oral anticoagulant therapy...
Med Lett Drugs Ther. 2024 Feb 5;66(1695):24 doi:10.58347/tml.2024.1695f | Show Introduction Hide Introduction
Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
, and decreases the
frequency of painful crises and the need for blood
transfusions.1 The amino acid L-glutamine ...
Two cell-based gene therapies – exagamglogene
autotemcel (Casgevy – Vertex) and lovotibeglogene
autotemcel (Lyfgenia – Bluebird Bio) – have been
approved by the FDA for treatment of sickle cell
disease in patients ≥12 years old with recurrent vaso-occlusive
crises. They are the first gene therapies to
be approved in the US for use in sickle cell disease;
Casgevy is the first treatment to be approved in the
US that uses CRISPR/Cas9 gene-editing technology.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):9-10 doi:10.58347/tml.2024.1694a | Show Introduction Hide Introduction
Bimekizumab (Bimzelx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
is generally limited to a maximum of 1-2 years
because of toxicity, especially the risk of irreversible ...
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx
– UCB) for treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic
treatment or phototherapy. Bimekizumab is the first
IL-17A/17F antagonist to be approved in the US. It
was approved in the European Union for the same
indication in 2021.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):11-3 doi:10.58347/tml.2024.1694b | Show Introduction Hide Introduction
Perfluorohexyloctane Ophthalmic Solution (Miebo) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
is increasing,
possibly because of increased screen time.1
STANDARD TREATMENT ― Treatments for dry eye ...
The FDA has approved perfluorohexyloctane
ophthalmic solution (Miebo – Bausch+Lomb) for
treatment of dry eye disease. Available only by
prescription, Miebo is the first ophthalmic product to be approved in the US that specifically targets tear
evaporation caused by meibomian gland dysfunction.
An ophthalmic solution with a similar name, Meibo
Tears (Vista), which contains 0.6% propylene glycol, is
available over the counter for dry eye relief.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):13-4 doi:10.58347/tml.2024.1694c | Show Introduction Hide Introduction
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
), a complement C3 and C3b
inhibitor, was approved earlier.1
AGE-RELATED MACULAR DEGENERATION ― AMD
has two ...
The FDA has approved the complement C5 inhibitor
avacincaptad pegol (Izervay – Iveric) for intravitreal
treatment of geographic atrophy (GA) secondary
to age-related macular degeneration (AMD).
Avacincaptad pegol is the second complement
inhibitor to be approved in the US for this indication;
pegcetacoplan (Syfovre), a complement C3 and C3b
inhibitor, was approved earlier.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):15-6 doi:10.58347/tml.2024.1694d | Show Introduction Hide Introduction
Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination with cisplatin and gemcitabine for
first-line treatment of recurrent locally advanced or
metastatic nasopharyngeal carcinoma and for use as
monotherapy for treatment of recurrent unresectable
or metastatic nasopharyngeal carcinoma in adults
with disease progression on or after platinum-based
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment of
nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7 doi:10.58347/tml.2024.1694e | Show Introduction Hide Introduction
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
.............................................................................. p 1
CHA2DS2-VASc Scoring ............................................................. p 2
Oral ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
In Brief: Three New Injectable Antipsychotic Drugs
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
and aripiprazole have been available in
the US for years (see Table 1).1
EXTENDED-RELEASE INJECTABLE ...
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the FDA
for treatment of schizophrenia in adults. Rykindo and
Abilify Asimtufii are also approved for maintenance
treatment of bipolar I disorder in adults. Other
extended-release injectable formulations of
risperidone and aripiprazole have been available in
the US for years (see Table 1).
Med Lett Drugs Ther. 2023 Dec 25;65(1692):207-8 doi:10.58347/tml.2023.1692d | Show Introduction Hide Introduction
Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
in 2019.1
Key Points: Zuranolone (Zurzuvae)
Description: A GABAA receptor modulator and an analog ...
The FDA has approved the oral GABAA receptor
modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression
(PPD). Zuranolone is the second drug to be approved
for this indication; brexanolone (Zulresso), another
GABAA receptor modulator, was approved for IV
treatment of PPD in 2019.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):201-3 doi:10.58347/tml.2023.1692a | Show Introduction Hide Introduction